Ascendis Pharma Announces Long-Term Phase 2 Trial Data Demonstrating Sustained Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism
12/5 22:50
Ascendis Pharma reports sustained efficacy and safety of TransCon PTH in treating adults with hypoparathyroidism in Phase 2 trial....